BR112023018224A2 - Anticorpo cxcr5 anti-humano e usos do mesmo - Google Patents

Anticorpo cxcr5 anti-humano e usos do mesmo

Info

Publication number
BR112023018224A2
BR112023018224A2 BR112023018224A BR112023018224A BR112023018224A2 BR 112023018224 A2 BR112023018224 A2 BR 112023018224A2 BR 112023018224 A BR112023018224 A BR 112023018224A BR 112023018224 A BR112023018224 A BR 112023018224A BR 112023018224 A2 BR112023018224 A2 BR 112023018224A2
Authority
BR
Brazil
Prior art keywords
human
cxcr5 antibody
human cxcr5
cxcr5
antibody
Prior art date
Application number
BR112023018224A
Other languages
English (en)
Inventor
Kök Harunova Ayrin
Francisco Adrian
Liang Schweizer
Arturo Aldo Beltraminelli Nicola
Qian Zhang
Sami Ellouze
Stéphanie Beq
Yun-Yueh Lu
Original Assignee
Hifibio Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2021/111049 external-priority patent/WO2023010483A1/en
Application filed by Hifibio Hk Ltd filed Critical Hifibio Hk Ltd
Publication of BR112023018224A2 publication Critical patent/BR112023018224A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

anticorpo cxcr5 anti-humano e usos do mesmo. a presente invenção refere-se a anticorpos monoclonais e fragmentos de ligação a antígeno específicos para cxcr5 (humano) e métodos para usar os mesmos para tratar síndrome de sjögren, certos cânceres e distúrbios autoimunes, incluindo terapia de combinação.
BR112023018224A 2021-03-09 2022-03-09 Anticorpo cxcr5 anti-humano e usos do mesmo BR112023018224A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163158462P 2021-03-09 2021-03-09
PCT/CN2021/111049 WO2023010483A1 (en) 2021-08-05 2021-08-05 Anti-human cxcr5 antibody and uses thereof
PCT/US2022/019587 WO2022192423A1 (en) 2021-03-09 2022-03-09 Anti-human cxcr5 antibody and uses thereof

Publications (1)

Publication Number Publication Date
BR112023018224A2 true BR112023018224A2 (pt) 2024-01-30

Family

ID=83228276

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018224A BR112023018224A2 (pt) 2021-03-09 2022-03-09 Anticorpo cxcr5 anti-humano e usos do mesmo

Country Status (10)

Country Link
US (1) US20240158517A1 (pt)
EP (1) EP4305073A1 (pt)
JP (1) JP2024509946A (pt)
KR (1) KR20230154981A (pt)
CN (1) CN117279954A (pt)
AU (1) AU2022234328A1 (pt)
BR (1) BR112023018224A2 (pt)
CA (1) CA3211179A1 (pt)
TW (1) TW202304984A (pt)
WO (1) WO2022192423A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2195023T (pt) * 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
KR102262720B1 (ko) * 2014-04-28 2021-06-08 이카가쿠 소우야쿠 가부시키가이샤 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도

Also Published As

Publication number Publication date
US20240158517A1 (en) 2024-05-16
AU2022234328A1 (en) 2023-09-28
CN117279954A (zh) 2023-12-22
TW202304984A (zh) 2023-02-01
WO2022192423A1 (en) 2022-09-15
CA3211179A1 (en) 2022-09-15
KR20230154981A (ko) 2023-11-09
EP4305073A1 (en) 2024-01-17
JP2024509946A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
MD3328888T2 (ro) Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
BRPI0412245A (pt) anticorpos de rg1 e usos destes
BR112021014074A2 (pt) Proteínas de ligação ao antígeno anti-receptor il2 gama
EA202190378A1 (ru) Антитела против ifnar1 для лечения аутоиммунных заболеваний
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
ZA202008095B (en) Humanized antibodies against psma
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
CR20220288A (es) Anticuerpos contra integrina alfa 11 beta 1
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
ECSP21046332A (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2023005313A (es) Anticuerpos fcrn y metodos de uso de estos.
MX2019001970A (es) Anticuerpo o un fragmento de union a antigeno del mismo, capaz de unirse a un receptor humano de interleucina-6.
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
BR112023018224A2 (pt) Anticorpo cxcr5 anti-humano e usos do mesmo
MX2022001380A (es) Anticuerpos de fcrn y metodos de uso de los mismos.
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
MX2022007156A (es) Metodos de uso de anticuerpos anti-cd33.
ECSP19018367A (es) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
WO2023147489A3 (en) Anti-musk antibodies for use in treating neuromuscular disorders
MX2022002371A (es) Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma).